Rigel to Present at Stifel Healthcare Conference

               Rigel to Present at Stifel Healthcare Conference

PR Newswire

SOUTH SAN FRANCISCO, Calif., Sept. 6, 2013

SOUTH SAN FRANCISCO, Calif., Sept. 6, 2013 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the
company's chairman and chief executive officer, is scheduled to present a
company overview at the Stifel 2013 Healthcare Conference in Boston, MA on
Thursday, September 12th at 1:30 p.m. ET.

The presentation will be webcast live and can be accessed at
www.rigel.com.Please connect to Rigel's website several minutes prior to the
start of the live webcast to ensure adequate time for any software download
that may be necessary.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc.is a clinical-stage drug development company that
discovers and develops novel, small-molecule drugs for the treatment of
inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's
pioneering research focuses on intracellular signaling pathways and related
targets that are critical to disease mechanisms. The company currently has
five product candidates in clinical development: fostamatinib, an oral SYK
inhibitor for ITP; R333, a topical JAK/SYK inhibitor for discoid lupus, and
R348, a topical JAK/SYK inhibitor for dry eye – both in Phase 2 clinical
trials; and two oncology product candidates in Phase 1 development with
partners BerGenBio andDaiichi Sankyo.

Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com

SOURCE Rigel Pharmaceuticals, Inc.

Website: http://www.rigel.com